AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01208441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT01208441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breast biopsy
Study NCT01208441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study NCT01208441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT02108587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical coherence tomography
Description: Undergo optical coherence tomography
Study NCT05635539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Analimentary detoxication (ANADETO) weight loss based on very-low-calorie-diet
Description: calorie restriction to 50-100 kcal/day with fat-free vegetables (tomatoes and cucumbers) with mandatory salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day, walking at least 2,000 steps/day after normalized body temperature, and sexual self-restraint. The walking provided to promote of blood circulation and decrease in metabolic intoxication. The weight loss method lasted 14 days. Then the patients followed for 4-week a diet where they ate one meal a day without any food restriction.
Study NCT02489123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT02489123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01128894 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: albiglutide weekly subcutaneous injection
Study NCT01128894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
Study NCT02091050 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2D HDR planning
Description: HDR planning using simple radiograph (2D)
Study NCT02091050 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3D HDR planning
Description: HDR planning using computed tomography (3D)
Study NCT03958786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified Geriatric Evaluation
Description: * Questionnaires~* Self assessment questionnaires~* Mobility and balance tests
Study NCT03958786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling
Description: - Blood samples : 35 ml will be collected at baseline, after signature of written informed consent, 7 ml at M12
Study NCT00334724 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home blood pressure measurement
Description: Blood pressure controlled based on home blood pressure measurement
Study NCT00334724 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Office blood pressure measurement
Description: Blood pressure controlled based on office blood pressure measurement
Study NCT04785235 — intervention group
Intervention type: PROCEDURE
Intervention: Non-Surgical Periodontal Therapy
Study NCT02222051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: traditional chinese martial art meditative movement technique
Study NCT02222051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neck exercises
Description: group exercises for strengthening and stretching neck and back muslces to alleviate neck pain
Study NCT00153517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral versus vaginal metronidazole
Study NCT03437278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 120 mg or 24 mg, high and low doses respectively.
Study NCT03437278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ligelizumab
Description: Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 120 mg or 24 mg, high and low doses respectively.
Study NCT03437278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0 mg per 1 ml liquid injection once every 4 weeks.
Study NCT01135550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose dexamethasone
Description: Subject will receive 5 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4.
Study NCT01135550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose dexamethasone
Description: Subject will receive 1 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4.
Study NCT02070536 — intervention group
Intervention type: OTHER
Intervention: sRAGE
Study NCT02439437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial Intervention
Description: Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
Study NCT01477333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UT-15C SR
Description: Initiated at 0.125 mg BID, titrated as clinically indicated.
Study NCT01477333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyvaso Inhalation Solution
Description: Administered as at least 9 breaths 4 times daily for at least 4 weeks prior to Baseline
Study NCT03133520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow oxygen therapy
Description: High-flow nasal oxygen \[HFNO\] therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates \[of up to 60 L/min\] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
Study NCT02843204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Patients received i.v. pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
Study NCT02843204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients received i.v. pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
Study NCT00066157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Description: 50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months
Study NCT00066157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal estradiol
Description: 50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months
Study NCT00066157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone
Description: 2.5mg tablet daily for 12 months
Study NCT00066157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone
Description: 2.5mg tablet daily for 12 months
Study NCT00066157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Patch
Description: Transdermal placebo patch, changed every 3 days, for 12 months
Study NCT00066157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Transdermal placebo patch, changed every 3 days, for 12 months
Study NCT00066157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily for 12 months
Study NCT00066157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily for 12 months
Study NCT02963506 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02963506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab in different dosages.
Study NCT02843204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: about 10 billion cells in all, infusion in 3 times, i.v.
Study NCT00553956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy/Interpersonal Psychotherapy
Description: The experimental group will receive 5 weekly individual sessions of NET in addition to 3 weekly individual sessions of IPT.
Study NCT00144651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Description: 8mg/kg/4 weeks for 1 year
Study NCT03136328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATOC
Description: The intervention is to administer 68Ga-DOTATOC PET/CT for detecting NET.
Study NCT01228708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active implementation of a guideline for chronic disease
Description: Smoking cessation courses Remuneration to GPs for the planned follow-up and joint home visits Action card and sputum colour advice Webpage on How to live with COPD and the support the health system can provide Database with patients with COPD Feed-back from health centre to GPs, when patients have finished courses Fax from hospital to GPs, when patients with COPD is discharged Routines to recall patients for follow-ups Team audit, evaluate and adjust the strategies every 3rd month Joint home visit with GP and community nurse when a patient with COPD is discharged to plan future care Practice staff do part of follow-ups and monitoring Practice supervision with consultant in lung diseases Podcast with advice from specialists Guideline for COPD
Study NCT00874341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fruit and vegetable intervention
Description: Dose-response effect of fruit and vegetable intake (1-2 vs 4 vs 7 portions per day for 12 weeks)
Study NCT03840239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Oxaliplatin
Description: Drug: Capecitabine, Oxaliplatin
Study NCT03840239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: External beam radiotherapy to the primary tumor, regional lymph nodes and clinical target volume
Study NCT03840239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: 'Local excision' or 'Intersphincter resection' or 'Total mesorectal excision' or other surgeries
Study NCT03840239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watch and wait strategy
Description: Watch and wait strategy recommendation and discussion for cCR patients
Study NCT04876118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting machine will be used to perform the treatments.
Study NCT01780974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoic Acid plus Omega-3 Fatty Acids
Description: alpha lipoic acid (racemic) and fish oil concentrate
Study NCT01780974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules
Study NCT00928239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic sacropexy with mid vaginal attachment
Description: * supracervical hysterectomy for uterine prolapse~* exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~* dissection up to ventrolateral part of the levator ani muscle~* Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~* Two separate meshes, Gynemesh® (Johnson\&Johnson) a polypropylene mesh, for anterior and posterior compartment~* suturing of posterior mesh caudally to levator ani muscle and proximally 4cm from the apex of the vagina or cervical stump~* placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~* suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2
Study NCT00928239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sacropexy with caudal vaginal attachment
Description: * supracervical hysterectomy for uterine prolapse~* exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~* dissection up to ventrolateral part of the levator ani muscle~* Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~* Two separate meshes, Gynemesh® (Johnson\&Johnson) a polypropylene mesh, for anterior and posterior compartment~* suturing of posterior mesh caudally to the levator ani muscle and proximally at caudal part of the vagina or cervical stump~* placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~* suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2
Study NCT03276624 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CABG
Description: surgical revascularization of stenosed coranary arteries using arterial and venous grafts.
Study NCT01173094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Transluminal Angioplasty
Description: Before operation, take aspirin 100mg every day. During the operation, balloon is delivered by a catheter and positioned through the narrowing in the artery. Then expand the balloon against the wall of the blood vessel to provide a wider channel for blood.
Study NCT01173094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: below-knee arterial bypass
Description: Before operation, take aspirin 100mg every day. Perform bypass to below-knee(posterior tibial，anterior tibial or peroneal)arteries, saphenous vein graft with end to side anastomoses
Study NCT00904137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cast
Study NCT03861377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil R2
Description: 0,7 microg/kg
Study NCT00904137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Splint
Study NCT00904137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tape
Study NCT03529669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge™
Description: Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the sponge is pulled out it collects the cells from the lining of the gullet.
Study NCT01065883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community health worker
Description: community health workers will provide education in the home
Study NCT01065883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mailed information
Description: information will be mailed to the home on the same schedule as the experimental intervention
Study NCT03747562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, gabapentin capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, gabapentin powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
Study NCT03747562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, placebo capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, placebo powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
Study NCT03861377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil R4
Description: 1,1 microg/kg
Study NCT03861377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil R8
Description: 1,7 microg/kg
Study NCT04013477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207
Description: DA-5207 Transdermal Delivery System
Study NCT04013477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: donepezil HCl 10mg QD
Study NCT04498832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Study NCT04498832 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: SC
Study NCT00361348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palifermin
Study NCT00361348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Study NCT00361348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Study NCT00300898 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nucleoplasty
Study NCT00300898 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous decompression
Study NCT00300898 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervertebral electrothermal disc decompression (IDET)
Study NCT00300898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Study NCT01110876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.~Phase II Dose: MTD from Phase I.
Study NCT01110876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.~Phase II Dose: MTD from Phase I.
Study NCT01110876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 125 mg/m2 by mouth daily on days 1-7, 15-21 of each 28 day cycle.
Study NCT04398953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525
Description: TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
Study NCT01813708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Life-Style
Description: 16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
Study NCT01813708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative Education
Description: 16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
Study NCT02784197 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Phase Signal Recorder
Description: The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal.
Study NCT04200157 — intervention group
Intervention type: OTHER
Intervention: Online survey
Description: Subjects will complete a single survey that takes 5-10 minutes to complete
Study NCT04480125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 100mg D1-7
Study NCT04480125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30mg BIW PO